James E. Herndon II

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

Darell D. Bigner, Jie He, Roger E. McLendon, 2014, Oncotarget.

Comparison of performance status with peak oxygen consumption in operable patients with non‐small‐cell lung cancer

L. Jones, W. Hornsby, N. Eves, 2014, Respirology.

Aberrant p53 Staining Does Not Predict Cisplatin Resistance in Locally Advanced Non-Small Cell Lung Cancer

D. Klimstra, Mark R. Green, J. Kern, 2002, Cancer investigation.

Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center

A. Abernethy, A. Coan, H. Uronis, 2009, Supportive Care in Cancer.

Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors

M. Berger, R. McLendon, A. Friedman, 2003, Journal of Neuro-Oncology.

Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer

C. Anders, G. Broadwater, A. V. Van Swearingen, 2022, Breast Cancer Research and Treatment.

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

J. Herndon, N. Vogelzang, M. Green, 2001, Lung cancer.